Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma Files Its 2020 Universal Registration Document (Document D'enregistrement Universel) and 2020 Annual Report on Form 20-F

04/28/2021 | 01:00am EDT

MARSEILLE, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2020 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 27, 2021. It can be downloaded (in French) on the Company’s website and on the AMF’s website.

The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2020 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company’s website and on the SEC’s website.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com 

Information about Innate Pharma shares:

ISIN code
Ticker code
Euronext: IPH Nasdaq: IPHA

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Tel.: +33 (0)4 30 30 30 30

Innate Pharma
Tracy Rossin (Global/US)
Tel.: +1 240 801 0076

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72


Primary Logo

© GlobeNewswire 2021
All news about INNATE PHARMA
06/16GLOBAL MARKETS LIVE : Oracle, General Motors, Credit Suisse, Sony, Made.com...
06/16INNATE PHARMA  : Company to highlight lacutamab data in mycosis fungoides and sh..
06/16Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Co..
06/10INNATE PHARMA  : Presents New Data on Next-Generation NK Cell Engager Platform a..
06/10Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies
06/10Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform a..
06/09INNATE PHARMA  : New Lacutamab Data From Tellomak Trial to be Showcased in Oral ..
06/09New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation a..
06/03INNATE PHARMA  : Assemblee Generale Mixte
05/31NHTHERAGUIX : NH TherAguix and the CHU Grenoble-Alpes announce the publication o..
More news
Sales 2021 39,8 M 47,3 M 47,3 M
Net income 2021 -40,6 M -48,4 M -48,4 M
Net Debt 2021 27,3 M 32,5 M 32,5 M
P/E ratio 2021 -2,00x
Yield 2021 -
Capitalization 241 M 287 M 287 M
EV / Sales 2021 6,74x
EV / Sales 2022 3,35x
Nbr of Employees 244
Free-Float 75,2%
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 6,85 €
Last Close Price 3,05 €
Spread / Highest target 140%
Spread / Average Target 125%
Spread / Lowest Target 110%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.90.67%79 980
LONZA GROUP AG14.63%52 508
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367